On August 4, 2021, Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) (Editor’s Note: EVs is an abbreviation for “extracellular vesicles” of which exosomes are a subset.) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular Vesicles Derived from Cardiosphere-Derived Cells As a Potential Antishock Therapeutic,” was published in the August 2021 issue of the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery, in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).